An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 20 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nivolumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms CheckMate 9X8
Sponsors Bristol-Myers Squibb

22 Mar 2023 Status changed from active, no longer recruiting to completed.
20 Dec 2022 This trial has been Discontinued in Spain, According to European Clinical Trials Database record.
22 Jan 2022 Primary endpoint (Progression Free Survival (PFS)) has not been met, as per results presented at the 2022 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com